Description CJC-1295 DAC is a synthetic 29 amino acid analog of Growth Hormone-Releasing Hormone (GHRH). It is designed to potentially increase the endogenous production of growth hormone (GH). The addition of the Drug Affinity Complex (DAC) is intended to significantly extend the peptide’s half-life to approximately 8 days by allowing it to bind to plasma proteins like albumin.

Overview of Potential Research Areas

• Reduction of fat mass and promotion of protein synthesis for muscle mass.
• Improvement of bone mass and connective tissue strength.
• Support for deep sleep centers in the nervous system.

Chemical Makeup

• Molecular Formula: C152H252N44O42
• Molecular Weight: 3367.95 g/mol
• Other Titles: Tetrasubsituted GRF 1-29 with DAC

Mechanism of Action Research suggests CJC-1295 DAC elevates levels of IGF-1 by increasing GH production. Studies in 2006 showed that a single dose could increase mean GH secretion and IGF-I levels by about 50%, with effects lasting up to two weeks. Animal studies (GHRH knockout mice) indicated that the peptide could normalize growth and positively affect body composition by increasing muscle hypertrophy without increasing fat accumulation.

Half-life and Modifications Standard GHRH has a half-life of ~7 minutes. CJC-1295 without DAC has a half-life of ~30 minutes. With DAC technology and specific amino acid substitutions (at positions 2, 8, 15, and 27), the half-life is extended to 6–8 days, increasing resistance to enzymatic degradation by dipeptidyl peptidase-4.

Disclaimer All products are sold for research, laboratory, or analytical purposes only and are not for human consumption. Statements have not been evaluated by the FDA